Racura Oncology (ASX:RAC) secures Bellberry ethics approval for HARNESS-1, activating Chris O’Brien Lifehouse and Austin Health for its EGFR lung cancer trial.
Racura Oncology Surges on Trial Update
Racura Oncology (ASX: RAC) climbed 8.66 per cent on Friday to close at A$2.76, after the independent Safety Review Committee cleared the company to…